BioPlan Associates, Inc.

Are you ready for 2025? Order BioPlan Associates, Inc. 21st Annual Report and Survey of Biopharmaceutical?Manufacturing Capacity and Production today - https://rb.gy/jnqotl. Comprehensive study provides valuable insights into industry trends, challenges, and opportunities! Newest #bioprocess technologies in demand, most critical trends, 21 years of #outsourcing data; trends in #singleuse adoption, #downstreamprocessing, new #modalities (#celltherapy and #genetherapy) trends, capacity bottlenecks, hiring challenges, vendor price changes, and much more! 220 Biopharma companies surveyed 179 industry vendors and suppliers 23 Countries ~500 Pages 12 Chapters 200+ Graphs and 20+ Tables Subject Matter Experts providing deep analysis

Discover key insights in the 2024 Biopharmaceutical Manufacturing Report! #Biopharma #AnnualReport https://conta.cc/40TLksb

The contract development and manufacturing organization (CDMO) space appears to be set up for a significant rebound in the coming years, according to data pre-released from the CPHI Annual Report and Survey. This comes ahead of the CPHI Milan conference that the Bourne Partners team will be attending this week. Specifically, the CPHI data suggests that ~49% of the CDMO industry is “highly positive” on contract services over the next 18 months (vs 44% who are "neutral" and only 7% who were “negative”). Two top areas of focus for executives are manufacturing capacity shortages (related to the strong consumer demand for GLP-1 medications) and the impact of the BIOSECURE Act on global pharma supply chains. Of note, only 19% agreed that China-based CDMOs are “a threat and should be removed from Western supply chains” -- vs 38% of respondents who said that the BIOSECURE Act “sets a concerning precedent for the industry.” This optimism going into the CPHI Milan conference closely follows similar optimism that we heard at the Contract Pharma 2024 Contracting and Outsourcing Conference in New Brunswick, New Jersey (September 26-27). At a presentation we attended by BioPlan Associates, Inc., CDMO bioprocessing demand is expected to reaccelerate to 10%-14% annually (vs 8.5% in 2023 and 2024) -- essentially in line with pre-COVID demand trends. Key drivers for CDMO demand that came up in our discussions include, among others, access to specialized staff, innovative biologics (e.g., cell/gene therapies, antibody-drug conjugates, etc.), emerging markets, novel production technologies (e.g., continuous bioprocessing, single-use, etc.), and capital avoidance (especially for smaller developers).

Survey Says Downstream Biomanufacturing Bottleneck Is Over https://lnkd.in/eVQ63Hq3 - By Ioanna Deni, BioPlan Associates, Inc. Today, 38% of eight biomanufacturing facilities are now reporting experiencing only “minor capacity bottlenecks” related to DSP.

Join Eric Langer, BioPlan Associates, Inc. and #Biopharma #CMO Industry Leaders at the 2024 Contract Pharma Annual Contracting and Outsourcing Conference as we talk about "Critical Trends & Growth in Biopharma Contract Manufacturing" - https://rb.gy/mopi78 Dive into current and future trends, engage in interactive sessions, and network to drive progress. Mark your calendar for Sept 26-27, 2024, at the Hyatt Regency in New Brunswick, NJ. Don't miss out on the latest technology and insights! #biopharma #contractmanufacturing #conference

ORDER BioPlan Associates, Inc. 2024 21st Annual Report and Survey of #Biopharmaceutical Manufacturing Capacity and Production to get the most extensive and longest-running survey of bioprocessing professionals - https://rb.gy/1ww0os A must-have resource for staying ahead in #biomanufacturing. This comprehensive study provides valuable insights into #bioprocessing industry trends, challenges, and opportunities - https://rb.gy/1ww0os Newest #bioprocess technologies in demand, most critical trends, 21 years of #outsourcing data; trends in single-use adoption, downstream processing, new modalities like #celltherapy and #genetherapy trends, #capacity bottlenecks, hiring challenges, vendor price changes, and much more! 220 Biopharma companies surveyed 179 industry vendors and suppliers 23 Countries ~500 Pages 12 Chapters 200+ Graphs and 20+ Tables Subject Matter Experts providing deep analysis FREE FOR FIRST TIME BUYERS: TOP 10 TRENDS IN MANUFACTURING, 2024?-?Top 10 Trends in bioprocessing provides key trends identified in this year's 21st Annual Report and Survey - https://rb.gy/trxtvb

Join Eric Langer, BioPlan Associates, Inc. at the 2024 Contract Pharma Annual Contracting and Outsourcing Conference as we talk about "Critical Trends & Growth in Biopharma Contract Manufacturing" - https://rb.gy/mopi78 Learn from industry leaders, engage in interactive sessions, and network to drive progress. Mark your calendar for Sept 26-27, 2024, at the Hyatt Regency in New Brunswick, NJ. Don't miss out on the latest technology and insights! #biopharma #contractmanufacturing #conference

Wish #SUS Cost Less? Survey Says Your Peers Do, Too https://rb.gy/mr9die - By Ioanna Deni, BioPlan Associates, Inc. Contributing Author. New article posted by Bioprocess Online. According to BioPlan Associates, Inc. 21st?Annual Report, single most important new product development area that suppliers need to focus their efforts on is low-cost single-use systems (SUS), with 32.3% of #biomanufacturing professionals reporting it in 2024.

Join Eric Langer, BioPlan Associates, Inc. at the 2024 Contract Pharma Annual Contracting and Outsourcing Conference as we talk about "Critical Trends & Growth in Biopharma Contract Manufacturing" - https://rb.gy/mopi78 Learn from industry leaders, engage in interactive sessions, and network to drive progress. Mark your calendar for Sept 26-27, 2024, at the Hyatt Regency in New Brunswick, NJ. Don't miss out on the latest technology and insights! #biopharma #contractmanufacturing #conference

Hear from industry experts, including BioPlan Associates, Inc. - Eric Langer, as they discuss the latest technology at this year’s Sartorius PI Forum, September 17-19 in G?ttingen, Germany - https://rb.gy/jre8xt Eric Langer will be discussing Trends in Process Intensification and Continuous Bioprocessing: Challenges and Opportunities Discover the latest technology and insight at this year’s Process Intensification Forum — three days of industry-leading speakers, interactive demonstrations, and networking sessions centered on sharing knowledge and driving progress. Sartorius PI Forum, September 17-19 in G?ttingen, Germany - https://rb.gy/jre8xt